Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy

被引：38
作者：
Benitez, Jose Carlos [1 ]
Remon, Jordi [2 ]
Besse, Benjamin [1 ,3 ]
机构：
[1] Gustave Roussy, Dept Canc Med, Villejuif, France
[2] HM Hosp, Hosp HM Delfos, Ctr Integral Oncol Clara Campal HM CIOCC, Dept Med Oncol, Barcelona, Spain
[3] Univ Paris Saclay, Orsay, France
来源：
CLINICAL CANCER RESEARCH | 2020年 / 26卷 / 19期
关键词：
CELL LUNG-CANCER; MAJOR PATHOLOGICAL RESPONSE; STAGE-III MELANOMA; BLADDER-CANCER; OPEN-LABEL; HIGH-RISK; CHEMOTHERAPY; THERAPY; SURVIVAL; OUTCOMES;
D O I：
10.1158/1078-0432.CCR-19-3255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immune checkpoint inhibitors (ICI) may overcome cancer cells' ability to evade the immune system and proliferate. The long-term benefit of ICI in the metastatic setting led to evaluate neoadjuvant ICI approaches in several tumor types such as melanoma, non-small cell lung cancer, and breast and bladder cancer. We summarize the current evidence for the efficacy of neoadjuvant ICI in cancer and discuss several unresolved challenges, including the role of adjuvant treatment after neoadjuvant ICI, the efficacy in oncogenic addicted tumors, and standardizing pathologic assessment.
引用
收藏
页码：5068 / 5077
页数：10
相关论文
共 82 条
  • [1] Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
    Amaria, Rodabe N.
    Menzies, Alexander M.
    Burton, Elizabeth M.
    Scolyer, Richard A.
    Tetzlaff, Michael T.
    Antdbacka, Robert
    Ariyan, Charlotte
    Bassett, Roland
    Carter, Brett
    Daud, Adil
    Faries, Mark
    Fecher, Leslie A.
    Flaherty, Keith T.
    Gershenwald, Jeffrey E.
    Hamid, Omid
    Hong, Angela
    Kirkwood, John M.
    Lo, Serigne
    Margolin, Kim
    Messina, Jane
    Postow, Michael A.
    Rizos, Helen
    Ross, Merrick I.
    Rozeman, Elisa A.
    Saw, Robyn P. M.
    Sondak, Vernon
    Sullivan, Ryan J.
    Taube, Janis M.
    Thompson, John F.
    van de Wiel, Bart A.
    Eggermont, Alexander M.
    Davies, Michael A.
    Ascierto, Paolo A.
    Spillane, Andrew J.
    van Akkooi, Alexander C. J.
    Wargo, Jennifer A.
    Blank, Christian U.
    Tawbi, Hussein A.
    Long, Georgina V.
    [J]. LANCET ONCOLOGY, 2019, 20 (07) : E378 - E389
  • [2] Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
    Amaria, Rodabe N.
    Reddy, Sangeetha M.
    Tawbi, Hussein A.
    Davies, Michael A.
    Ross, Merrick, I
    Glitza, Isabella C.
    Cormier, Janice N.
    Lewis, Carol
    Hwu, Wen-Jen
    Hanna, Ehab
    Diab, Adi
    Wong, Michael K.
    Royal, Richard
    Gross, Neil
    Weber, Randal
    Lai, Stephen Y.
    Ehlers, Richard
    Blando, Jorge
    Milton, Denai R.
    Woodman, Scott
    Kageyama, Robin
    Wells, Daniel K.
    Hwu, Patrick
    Patel, Sapna P.
    Lucci, Anthony
    Hessel, Amy
    Lee, Jeffrey E.
    Gershenwald, Jeffrey
    Simpson, Lauren
    Burton, Elizabeth M.
    Posada, Liberty
    Haydu, Lauren
    Wang, Linghua
    Zhang, Shaojun
    Lazar, Alexanderj
    Hudgens, Courtney W.
    Gopalakrishnan, Vancheswaran
    Reuben, Alexandre
    Andrews, Miles C.
    Spencer, Christine N.
    Prieto, Victor
    Sharma, Padmanee
    Allison, James
    Tetzlaff, Michael T.
    Wargo, Jennifer A.
    [J]. NATURE MEDICINE, 2018, 24 (11) : 1649 - +
  • [3] Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
    Amaria, Rodabe N.
    Prieto, Peter A.
    Tetzlaff, Michael T.
    Reuben, Alexandre
    Andrews, Miles C.
    Ross, Merrick J.
    Glitza, Isabella C.
    Cormier, Janice
    Hwu, Wen-Jen
    Tawbi, Hussein A.
    Patel, Sapna P.
    Lee, Jeffrey E.
    Gersbenwaid, Jeffrey E.
    Spencer, Christine N.
    Gopalakrishnan, Vancheswaran
    Bassett, Roland
    Simpson, Lauren
    Mouton, Rosalind
    Hudgens, Courtney W.
    Zhao, Li
    Zhu, Haifeng
    Cooper, Zachary A.
    Wani, Khalida
    Lazar, Alexander
    Hwu, Patrick
    Diab, Adi
    Wong, Michael K.
    McQuade, Jennifer L.
    Royal, Richard
    Lucci, Anthony
    Burton, Elizabeth M.
    Reddy, Sangeetha
    Sharma, Padmanee
    Allison, James
    Futreal, Phillip A.
    Woodman, Scott E.
    Davies, Michael A.
    Wargo, Jennifer A.
    [J]. LANCET ONCOLOGY, 2018, 19 (02) : 181 - 193
  • [4] Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Anagnostou, Valsamo
    Forde, Patrick M.
    White, James R.
    Niknafs, Noushin
    Hruban, Carolyn
    Naidoo, Jarushka
    Marrone, Kristen
    Sivakumar, I. K. Ashok
    Bruhm, Daniel C.
    Rosner, Samuel
    Phallen, Jillian
    Leal, Alessandro
    Adleff, Vilmos
    Smith, Kellie N.
    Cottrell, Tricia R.
    Rhymee, Lamia
    Palsgrove, Doreen N.
    Hann, Christine L.
    Levy, Benjamin
    Feliciano, Josephine
    Georgiades, Christos
    Verde, Franco
    Illei, Peter
    Li, Qing Kay
    Gabrielson, Edward
    Brock, Malcolm V.
    Isbell, James M.
    Sauter, Jennifer L.
    Taube, Janis
    Scharpf, Robert B.
    Karchin, Rachel
    Pardoll, Drew M.
    Chaft, Jamie E.
    Hellmann, Matthew D.
    Brahmer, Julie R.
    Velculescu, Victor E.
    [J]. CANCER RESEARCH, 2019, 79 (06) : 1214 - 1225
  • [5] [Anonymous], 2020, J CLIN ONCOL S
  • [6] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) : 2342 - 2350
  • [7] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
  • [8] Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity
    Bakos, Orneala
    Lawson, Christine
    Rouleau, Samuel
    Tai, Lee-Hwa
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [9] Bar J, 2019, J CLIN ONCOL S, V37, p15s
  • [10] Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer:: 5-year follow-up of a phase II study
    Betticher, DC
    Schmitz, SFH
    Tötsch, M
    Hansen, E
    Joss, C
    von Briel, C
    Schmid, R
    Pless, M
    Habicht, J
    Roth, AD
    Spiliopoulos, A
    Stahel, R
    Weder, W
    Stupp, R
    Egli, F
    Furrer, M
    Honegger, H
    Wernli, M
    Cerny, T
    Ris, HB
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (08) : 1099 - 1106
123456789